References

• Bottoni TN. Neuroleptic malignant syndrome: A brief review. Hosp Physician 2002; 38(3): 58–63.
   Google Scholar
• Delay J, Deniker P. Drug induced extrapyramidal syndromes. In: Viniken PJ, Bruyn GW, eds. Handbook of Clinical Neurology: Diseases of the Basal Ganglia. Vol 6. Amsterdam: Elsevier; 1968. p. 248–66.
   Google Scholar
• Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998; 49(9): 1163–72.
   PubMed Web of Science ®Google Scholar
• Silva RR, Munoz DM, Alpert M, Perlmutter IR, Diaz J. Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999; 38: 187–94.
   PubMed Web of Science ®Google Scholar
• Gelder M, Gath D, Mayou et al. The Neuroleptic Malignant Syndrome. Oxford Texbook of Psychiatry, Third edition. M Gelder, D Gath, R Mayou et al (ed), Oxford University Press; 1996. p. 554–5.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition, Washington DC: American Psychiatric Association; 1994. p. 739–42.
   Google Scholar
• Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164(6): 870–6.
   PubMed Web of Science ®Google Scholar
• Unal F, Hizli S, Ozyurek H, Sonuvar B. Fever and altered consciousness are not always equal to central nervous system infection: neuroleptic malignant syndrome in a 15-year-old girl. Turk J Pediatr 1996; 38(4): 505–10.
   Web of Science ®Google Scholar
• Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142(10): 1137–45.
   PubMed Web of Science ®Google Scholar
• Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: a review and analysis of 115 cases. Biol Psychiatry 1987; 22: 1004–20.
   PubMed Web of Science ®Google Scholar
• Numa A. Neuroleptic malignant syndrome in children. Med J Aust 1991; 155(6): 417–9.
   Web of Science ®Google Scholar
• Hillis RE, Lee DA. Viral encephalitis complicated by neuroleptic malignant syndrome in a 7-year-old girl. Pediatr Emerg Care 2003; 19(2): 99–100.
   Web of Science ®Google Scholar
• Hanft A, Eggleston C, Bourgeois JA. Neuroleptic malignant syndrome in adolescent after brief exposure to olanzapine. J Child Adolesc Psychopharmacol 2005; 14(3): 481–7.
   Web of Science ®Google Scholar
• Abu-Kishk I, Toledano M, Reis A, Daniel D, Berkovitch M. Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic. J Toxicol Clin Toxicol 2004; 42(6): 921–5.
   PubMed Web of Science ®Google Scholar
• Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 2004; 26(7): 1105–8.
   Web of Science ®Google Scholar
• Chungh DS, Kim BN, Cho SC. Neuroleptic malignanat syndrome due to three atypical antipsychotics in a child. J Psychopharmacol 2005; 19(4): 422–5.
   Web of Science ®Google Scholar
• Memik NC, Karakaya I, Coskun A, Ağaoğlu B. Neuroleptic malignant syndrome in early adolescence: a case report. Turkish Journal of Child and Adolescent Mental Health 2006; 13(3): 124–9.
   Google Scholar
• Edna B. Ty and A. David Rothner Topical Review: Neuroleptic Malignant Syndrome in Children and Adolescents J Child Neurol 2001; 16(3): 157
   Web of Science ®Google Scholar
• Moyes DJ. Malignant hyperpyrexia caused by trimeprazine. Br J Anaesth 1973; 45(11): 1163–4.
   Web of Science ®Google Scholar
• Randolph TC. Possible contribution of XYY syndrome to neuroleptic malignant syndrome in a child receiving quetiapine. Am J Health Syst Pharm 2010; 67(6): 459–61.
   PubMed Web of Science ®Google Scholar
• Naganuma H, Fujii I. Incidence and risk factors in neuroleptic malignant syndrome. Acta Psychiatr Scand 1994; 90(6): 424–6.
   Web of Science ®Google Scholar
• Nishijima K, Ishiguro T. Clinical course and CSF monoamine metabolism in neuroleptic malignant syndrome-a study of nine typical cases and five mild cases. Seishin Shinkeigaku Zasshi 1989; 91(6): 429–56.
   Google Scholar
• Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65(4): 464–70.
   PubMed Web of Science ®Google Scholar
• Nisijiama K, Ishiguro T. Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. Biol Psychiatry 1990; 27(3): 280–8.
   Web of Science ®Google Scholar
• Rosebush P and Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989; 146(6): 717–25.
   Web of Science ®Google Scholar
• Steingard R, Khan A, Gonzales A, Herzog D. Neuroleptic malignant syndrome: review of experience with children and adolescents. J Child Adolesc Psychopharmacol 1992; 2(3): 183–98.
   Google Scholar
• Herken H, Kaya N, Askın R, Kucur R. Nöroleptik malign sendrom: 5 olgu sunumu. Klinik Psikiyatri Dergisi 1998; 1(2): 120–4.
   Google Scholar
• Ram A, Cao Q, Keck JR, Pope HG Jr, Otani K, Addonizio G et al. Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome. Am J Med Genet 1995; 60(3): 228–30.
   Web of Science ®Google Scholar
• Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77(1): 185–202.
   PubMed Web of Science ®Google Scholar
• Azorin JM, Bouchacourt M, Lavergne T, Giudicelli S. Syndrome malin des neuroleptiques. Efficacité de la bromocriptine. Presse Med 1984; 13(27): 1702.
   Google Scholar
• Mueller PS, Vester JW, Fermaglich J. Neuroleptic malignant syndrome: Successful treatment with bromocriptine. JAMA 1983; 249(3): 386–8.
   Web of Science ®Google Scholar
• Sakkas P, Davis JM, Janicak PG. Drug treatment of neuroleptic malignant syndrome. Psychopharmacol Bull 1991; 27(3): 381–4.
   PubMedGoogle Scholar
• Turk J, Lask B. Neuroleptic malignant syndrome. Arch Dis Child 1991; 66(1): 91–2.
   Web of Science ®Google Scholar